A Phase 3 interventional study of Apatinib and Etoposide in Ovarian Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-08.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing apatinib in Ovarian Neoplasms — 6 open to participants now, 6 under way, 1 of them phase 3. apatinib · Ovarian Neoplasms.
Among the 22 studies testing apatinib in Ovarian Neoplasms, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2019, is one of 3 in phase 3, and was the 11th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →6 of the 22 studies testing apatinib in Ovarian Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70 · Women only
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
The First Affiliated Hospital of Xiamen University
Ages 18–75 · Women only
Guangxi Medical University · Sites in China
Ages 18–75 · Women only
Jin Li
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 280 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 59 across the 22 interventional studies. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 22 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd.: 6 open now, 6 under way, 4 of them phase 3. Of 7 finished, 0 (0%) have results posted.
Among the 16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 6th largest by planned enrollment, is one of 2 that started in 2019, is one of 6 in phase 3, and was the 5th registered.
Jiangsu HengRui Medicine Co., Ltd.’s Ovarian Neoplasms studies by the year they started, since 2015.
1 of the studies testing apatinib in Ovarian Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07033819Cancer Institute and Hospital, Chinese Academy of Medical SciencesNeoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib | 2027-06-20 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing apatinib in Ovarian Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Jiangsu HengRui Medicine Co., Ltd.’s 16 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with platinum resistant or refractory ovarian cancer compared with weekly paclitaxel (80 mg/m2, d1, d8, d15, q3w).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
Drug: Apatinib · Drug: Etoposide
Weekly Paclitaxel (80 mg/m2, d1, d8, d15, q3w) until disease progression or intolerable toxicity
Drug: Paclitaxel
Subjects receive Apatinib orally, Dosage form: tablet, Strength: 375 mg/d
Subjects receive Etoposide capsule orally, d1-14, q3w, Dosage form: capsule, Strength: 50 mg/d
Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, q3w, Dosage form: injectable, Strength: 80 mg/m2
Progression free survival(PFS) by independent review committee(IRC)
PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the IRC according to the RECIST criteria
Time frame: up to approximately 2 years
The incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Frequency and severity of Adverse Events or Serious Adverse Events as defined by CTCAE version 5.0
Time frame: up to approximately 2 years
PFS by investigator
PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigator according to the RECIST criteria
Time frame: up to approximately 2 years
Objective Response Rate (ORR)
Proportion of subjects who have a complete or partial response relative to baseline as assessed per RECIST 1.1 criteria as well as Gynecologic Cancer Intergroup (GCIG) cancer antigen (CA)-125 criteria.
Time frame: up to approximately 2 years
Overall Survival (OS)
OS is the time interval from the date of randomization to death from any cause.
Time frame: up to approximately 3 years
EQ-5D-5L questionnaire
EQ-5D-5L is a questionnaire that focus on issues specific to ovarian cancer.
Time frame: up to approximately 2 years
FOSI-8 questionnaire
FOSI-8 is a questionnaire that focus on issues specific to ovarian cancer.
Time frame: up to approximately 2 years
Plan to share: No — All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.
No publications or documents are linked to this record.
Started Aug 2019 (actual). Primary completion is estimated for Jan 2021, 17 months after the start.
Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 17 months is below that.
Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Apatinib · Etoposide
Jiangsu HengRui Medicine Co., Ltd. →